Rajiv Sarman Shukla

Avendus Capital Pvt Ltd. provides financial services. The firm offers financial advisory, mergers and acquisitions, private equity syndication, equity capital markets, structured finance, financial sponsors group, wealth management, alternative asset management, and institutional equities. The company was founded by Ranu Vohra, Gaurav Deepak and Kaushal Aggarwal and is headquartered in Mumbai, India.

Bharat Biotech International Ltd. engages in research and development, manufacturing, marketing and distribution of vaccines and biotherapeutics. It focuses on the development of novel health care solutions for region-specific neglected diseases. The firm offers Revac-B+, REGEN-D, HNVAC, COMVAC5, BIOPOLIO, INDIRAB, Typbar TCV, BIOHIB, JENVAC, ROTAVAC and vaccine candidates against chikungunya, chandipura, HPV and Ebola. The company was founded by Krishna Murthy Ella and Suchitra K. Ella in 1996 and is headquartered in Hyderabad, India..

I-VEN Medicare India Pvt Ltd. provides investment services in the healthcare sectors. It invests in hospitals and research institutes. The company is headquartered in Bangalore, India.

Constellation Alpha Capital Corp. is a blank check company, which engages in the in a share exchange, share reconstruction, amalgamation, acquisition, and business combination with businesses or entities. The company was founded by Rajiv Sarman Shukla on July 31, 2015 and is headquartered in West Palm Beach, FL.

Alpha Healthcare Acquisition Corp. operates as a blank check company, which is formed in order to effect a merger, capital stock exchange, asset acquisition, stock purchase, and reorganization or similar business combination with one or more businesses or entities. The company was founded on July 1, 2020 and is headquartered in New York, NY.

InflammX Therapeutics, Inc. is a biopharmaceutical company that focuses on targeting the NLRP3 inflammasome pathway of inflammation. The private company is based in Tampa, FL. The company has identified the key disease-related upstream trigger for inflammasome activation and its therapeutics target this trigger. Its lead product, Xiflam™, is set to enter phase 2b clinical trials in the fourth quarter of 2022. In addition, InflammX has a follow-on pre-clinical peptide program that also targets the dysregulated NLRP3 inflammasome, which will be developed following additional funding being raised. The company was founded by Colin Richard Green, and the CEO is Brian Levy.

Alpha Healthcare Acquisition Corp. III is a blank check company, which engages in the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded on January 21, 2021 and is headquartered in New York, NY.